JAZZ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
JAZZ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Jazz Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2024 was $1,127 Mil.
Jazz Pharmaceuticals's quarterly retained earnings increased from Jun. 2024 ($871 Mil) to Sep. 2024 ($936 Mil) and increased from Sep. 2024 ($936 Mil) to Dec. 2024 ($1,127 Mil).
Jazz Pharmaceuticals's annual retained earnings increased from Dec. 2022 ($734 Mil) to Dec. 2023 ($879 Mil) and increased from Dec. 2023 ($879 Mil) to Dec. 2024 ($1,127 Mil).
The historical data trend for Jazz Pharmaceuticals's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Retained Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
1,159.89 | 830.23 | 733.59 | 878.66 | 1,127.35 |
Jazz Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Retained Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
878.66 | 864.04 | 871.18 | 936.23 | 1,127.35 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Jazz Pharmaceuticals (NAS:JAZZ) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Bruce C Cozadd | director, officer: Executive Chairman | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 00000 |
Robert Iannone | officer: EVP, Research & Development | 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950 |
Patricia Carr | officer: VP, Finance& PAO | JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Neena M Patil | officer: SVP, General Counsel | JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Mary Elizabeth Henderson | officer: SVP, Technical Operations | 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Jennifer E. Cook | director | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Mark Douglas Smith | director | C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Patrick G Enright | director, 10 percent owner | CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Catherine A. Sohn | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Rick E Winningham | director | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Heather Ann Mcsharry | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Peter Gray | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Anne Oriordan | director | HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK |
Kenneth W O'keefe | director | C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603 |
From GuruFocus
By PRNewswire • 02-20-2025
By GuruFocus News • 04-09-2025
By GuruFocus News • 04-04-2025
By GuruFocus News • 04-14-2025
By PRNewswire • 12-05-2024
By PRNewswire • 02-25-2025
By GuruFocus News • 03-04-2025
By ACCESSWIRE • 02-07-2025
By GuruFocus News • 02-28-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.